COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
T Fiolet, Y Kherabi, CJ MacDonald, J Ghosn… - Clinical Microbiology …, 2022 - Elsevier
Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
Bivalent omicron BA. 1–adapted BNT162b2 booster in adults older than 55 years
P Winokur, J Gayed, D Fitz-Patrick… - … England Journal of …, 2023 - Mass Medical Soc
Background The emergence of immune-escape variants of severe acute respiratory
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide …
syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide …
Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021
Importance Vaccination against COVID-19 provides clear public health benefits, but
vaccination also carries potential risks. The risks and outcomes of myocarditis after COVID …
vaccination also carries potential risks. The risks and outcomes of myocarditis after COVID …
Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age
FM Muñoz, LD Sher, C Sabharwal… - … England Journal of …, 2023 - Mass Medical Soc
Background Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are
urgently needed in young children. Methods We conducted a phase 1 dose-finding study …
urgently needed in young children. Methods We conducted a phase 1 dose-finding study …
Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age
Background Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are
urgently needed in children younger than 12 years of age. Methods A phase 1, dose-finding …
urgently needed in children younger than 12 years of age. Methods A phase 1, dose-finding …
Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
HM El Sahly, LR Baden, B Essink… - … England Journal of …, 2021 - Mass Medical Soc
Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA
vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory …
vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory …
Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age
Background The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273
coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. Methods Part …
coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. Methods Part …
[HTML][HTML] Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years …
LD Zambrano - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
The Pfizer-BioNTech vaccine, currently authorized for persons aged≥ 5 years, provides a
high level of protection against severe COVID-19 in persons aged 12–18 years. Vaccine …
high level of protection against severe COVID-19 in persons aged 12–18 years. Vaccine …